Effects of oral estradiol and levonorgestrel on cardiovascular risk markers in postmenopausal women

Archives of Gynecology and Obstetrics

Volumn 285, Issue 6, 2012, Pages 1647-1656

  Terauchi, Masakazu ^a   Honjo, Hideo ^b   Mizunuma, Hideki ^c   Aso, Takeshi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Kyoto Gakusai Institute   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

Author keywords

Blood coagulation factors; Hormone replacement therapy; Lipids; Lipoproteins; Menopause

Indexed keywords

ANTITHROMBIN; CHOLESTEROL; ESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVONORGESTREL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROTEIN C; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DOSE RESPONSE; FEMALE; FIBRINOLYSIS; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRIACYLGLYCEROL BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FIBRINOGEN; HUMANS; LEVONORGESTREL; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; POSTMENOPAUSE; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; TRIGLYCERIDES;

EID: 84864439996     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-012-2222-9     Document Type: Article

References (30)

1. Thom T, Haase N, Rosamond W et al (2006) Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113:e85-e151
2. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ (2000) A prospective, observational study of post-menopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 133:933-941
3. Grodstein F, Manson JE, Stampfer MJ (2001) Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study: a prospective, observational study. Ann Intern Med 135:1-8
4. Hulley S, Grady T, Bush T et al (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605-613
5. Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 288:321-333
6. Manson JE, Bassuk SS, Harman SM et al (2006) Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause 13:139-147
7. Salpeter S, Walsh J, Greyber E, Salpeter E (2006) Brief report: coronary heart disease events associated with hormone therapy in younger and older women. J Gen Intern Med 21:363-366
8. Rossouw JE, Prentice RL, Manson JE et al (2007) Postmeno-pausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297:1465-1477
9. Writing Group on behalf of Workshop Consensus Group (2009) Aging, menopause, cardiovascular disease and HRT. International menopause society consensus statement. Climacteric 12:368-377
10. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice (2008) ACOG Committee Opinion No. 420, November 2008: hormone therapy and heart disease. Obstet Gynecol 112:1189-1192
11. Godsland IF (2001) Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 75:898-915
12. Løkkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Ø Lidegaard (2008) Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J 29:2660-2668
13. Birkhäuser MH, Panay N, Archer DF et al (2008) Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 11:108-123
14. Honjo H, Taketani Y (2009) Low-dose estradiol for climacteric symptoms in Japanese women: a randomized, controlled trial. Climacteric 12:319-328
15. Mizunuma H, Taketani Y, Ohta H et al (2010) Dose effects of oral estradiol on bone mineral density in Japanese women with osteoporosis. Climacteric 13:72-83
16. Wakatsuki A, Okatani Y, Ikenoue N, Shinohara K, Watanabe K, Fukaya T (2003) Effect of lower dose of oral conjugated equine estrogen on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 108:808-813
17. Villa P, Sagnella F, Perri C et al (2008) Low- and standardestrogen dosage in oral therapy: dose-dependent effects on insulin and lipid metabolism in healthy postmenopausal women. Climacteric 11:498-508
18. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T (2002) Different effects of oral conjugated equine estrogen and transdermal estrogen replacement therapy on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 106:1771-1776
19. Di Angelantonio E, Sarwar N, Perry P et al (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302:1993- 2000
20. Miller M, Stone NJ, Ballantyne C et al (2011) Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 123:2292-2333
21. Woodard GA, Brooks MM, Barinas-Mitchell E, Mackey RH, Matthews KA, Sutton-Tyrrell K (2011) Lipids, menopause, and early atherosclerosis in Study of Women's Health Across the Nation Heart women. Menopause 18:376-384
22. Lobo RA, Bush T, Carr BR, Pickar JH (2001) Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 76:13-24
23. Collins P, Flather M, Lees B, Mister R, Proudler AJ, Stevenson JC (2006) Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. Eur Heart J 27:2046- 2053
24. Manson JE, Hsia J, Johnson KC et al (2003) Estrogen plus pro-gestin and the risk of coronary heart disease. N Engl J Med 349:523-534
25. Anderson GL, Limacher M, Assaf AR et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712
26. Nair GV, Chaput LA, Vittinghoff E et al (2005) Pulse pressure and cardiovascular events in postmenopausal women with coronary heart disease. Chest 127:1498-1506
27. Margolis KL, Bonds DE, Rodabough RJ et al (2004) Effect of oestrogen plus progestin on the incidence of diabetes in post-menopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 47:1175-1187
28. Bonds DE, Lasser N, Qi L et al (2006) The effect of conjugated equine oestrogen on diabetes incidence: the Women's Health Initiative randomised trial. Diabetologia 49:459-468
29. Kanaya AM, Herrington D, Vittinghoff E et al (2003) Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study: a randomized, doubleblind, placebo-controlled trial. Ann Intern Med 138:1-9
30. Mosca L, Benjamin EJ, Berra K et al (2011) Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American heart association. Circulation 123:1243-1262